Trading Signals: SAGE Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Fri. Dec. 22, 2023)(SAGE Therapeutics Inc)
| SAGE latest price $163.4900 (-0.2%) ($161.1700 - $164.9800) on Thu. Sep. 6, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.16% (three month average) | RSI | 76 | Latest Price | $163.4900(-0.2%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | SAGE advances 4.1% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support SAGE advance at 0% a week (0% probability) IBB(50%) XBI(47%) IWO(46%) IWC(43%) IWM(42%) | Factors Impacting SAGE price | SAGE will decline at least -1.58% in a week (0% probabilities). VXX(-11%) VIXM(-11%) UUP(-11%) TLT(-7%) SHY(-4%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.58% (StdDev 3.16%) | Hourly BBV | 0 () | Intraday Trend | -0.4% | | | |
|
5 Day Moving Average | $164.14(-0.4%) | 10 Day Moving Average | $161.1(1.48%) | 20 Day Moving Average | $155.85(4.9%) | To recent high | -7% | To recent low | 13.3% | Market Cap | $8.491b | | | | SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA. |